New Pharmacological Treatments for Attention Deficit Hyperactivity Disorder (ADHD) – Viloxazine | Azstarys | Mazindol | Centanafadine
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by inattention, disorganisation, and/or hyperactive impulsivity. [Simon et al. 2009]
It affects up to 5% of children. It causes substantial functional impairment (e.g., social, academic, and occupational), reduced quality of life, and a higher risk of obesity, substance abuse, and suicide compared with the general population. [APA 2013]; [Faraone et al. 2015]
Approximately 20% of patients either do not tolerate existing therapies or experience insufficient efficacy. Therefore, given ADHD is a chronic disorder, has a high rate of comorbidities, and is life-long, there is a real medical need for treatments that span the lifespan from childhood to adulthood.
Coghill, D. R., Banaschewski, T., Soutullo, C., Cottingham, M. G., & Zuddas, A. (2017). Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. European child & adolescent psychiatry, 26(11), 1283-1307.